Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management Has $31.66 Million Stake in Teva Pharmaceutical Industries Ltd (TEVA)

Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management grew its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 18.8% during the first quarter, HoldingsChannel.com reports. The firm owned 2,018,926 shares of the company’s stock after buying an additional 320,000 shares during the period. Teva Pharmaceutical Industries makes up about 1.8% of Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management’s holdings, making the stock its 9th biggest holding. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management’s holdings in Teva Pharmaceutical Industries were worth $31,657,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Northstar Group Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 34.9% in the 4th quarter. Northstar Group Inc. now owns 15,468 shares of the company’s stock valued at $239,000 after purchasing an additional 4,000 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of Teva Pharmaceutical Industries by 3.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 49,181 shares of the company’s stock valued at $758,000 after buying an additional 1,681 shares in the last quarter. Cacti Asset Management LLC increased its position in shares of Teva Pharmaceutical Industries by 12.5% in the 4th quarter. Cacti Asset Management LLC now owns 577,904 shares of the company’s stock valued at $8,911,000 after buying an additional 64,180 shares in the last quarter. AGF Investments America Inc. increased its position in shares of Teva Pharmaceutical Industries by 2.5% in the 4th quarter. AGF Investments America Inc. now owns 60,321 shares of the company’s stock valued at $930,000 after buying an additional 1,458 shares in the last quarter. Finally, Boston Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 18.0% in the 4th quarter. Boston Advisors LLC now owns 23,555 shares of the company’s stock valued at $363,000 after buying an additional 3,592 shares in the last quarter. 67.28% of the stock is currently owned by institutional investors.

TEVA has been the subject of a number of recent analyst reports. ValuEngine cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Bank of America upgraded shares of Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 price objective for the company in a research report on Thursday, January 3rd. Zacks Investment Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Monday, January 21st. UBS Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research report on Wednesday, January 23rd. Finally, Piper Jaffray Companies upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $15.00 to $16.00 in a research report on Wednesday, January 23rd. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $20.84.

TEVA stock opened at $15.36 on Monday. The stock has a market cap of $15.62 billion, a price-to-earnings ratio of 5.49, a PEG ratio of 2.94 and a beta of 1.33. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.96 and a quick ratio of 0.63. Teva Pharmaceutical Industries Ltd has a 1 year low of $14.04 and a 1 year high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, February 13th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.53. The firm had revenue of $4.56 billion during the quarter, compared to analysts’ expectations of $4.52 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.57% and a negative net margin of 11.40%. The company’s revenue was down 15.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.3 earnings per share for the current year.

In other news, insider Deborah A. Griffin sold 4,107 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $69,326.16. Following the completion of the transaction, the insider now owns 2,941 shares in the company, valued at approximately $49,644.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Notaristefani Carlo De sold 5,041 shares of the firm’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $17.88, for a total value of $90,133.08. Following the completion of the transaction, the vice president now owns 17,162 shares of the company’s stock, valued at approximately $306,856.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,691 shares of company stock valued at $283,458. Corporate insiders own 0.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://transcriptdaily.com/2019/04/29/mivtachim-the-workers-social-insurance-fund-ltd-under-special-management-has-31-66-million-stake-in-teva-pharmaceutical-industries-ltd-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Benefits of owning preferred stock

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.